Clinical Trial: A First-in-human Study of KT502 Administered Subcutaneously to Adult Participants With Rheumatoid Arthritis (RA)

U.S., May 5 -- ClinicalTrials.gov registry received information related to the study (NCT07564154) titled 'A First-in-human Study of KT502 Administered Subcutaneously to Adult Participants With Rheumatoid Arthritis (RA)' on April 27.

Brief Summary: This is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT502 administered subcutaneously to participants with Rheumatoid Arthritis (RA). The study will have 2 parts: Part A is a single ascending dose finding (SAD) and Part B is dose escalation by fractionated dosing.

Study Start Date: July, 2026

Study Type: INTERVENTIONAL

Condition: Rheumatoid Arthritis (RA)

Intervention: DRUG: KT502

KT502 is a monoclonal antib...